Lexicon Pharmaceuticals (LXRX) Net Equity Issued and Repurchased (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Net Equity Issued and Repurchased of $70.0 million for Q1 2026, up 128.99% quarter-over-quarter from -$241.4 million in Q4 2024.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Net Equity Issued and Repurchased (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Net Equity Issued and Repurchased for 15 consecutive years, with $70.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $70.0 million; the TTM figure through Mar 2026 stood at $70.0 million (up 128.99% YoY), while the FY2021 annual figure was $37.1 million, down 47.0% from the prior year.
- Net Equity Issued and Repurchased rose to $70.0 million in Q1 2026 per LXRX's latest filing, from -$241.4 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $241.4 million in Q1 2024 and bottomed at -$241.4 million in Q4 2024.
- Historically, Net Equity Issued and Repurchased has averaged -$2.7 million across 4 years, with a median of -$15000.0 in 2024.
- Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased tumbled 24972.82% — and 2024, when it surged 94.35%.
- Lexicon Pharmaceuticals' Net Equity Issued and Repurchased stood at -$94.3 million in 2022, then tumbled by 47.26% to -$138.8 million in 2023, then sank by 73.89% to -$241.4 million in 2024, then surged by 128.99% to $70.0 million in 2026.
- Business Quant data shows LXRX's Net Equity Issued and Repurchased at $70.0 million in Q1 2026, -$241.4 million in Q4 2024, and -$10000.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | 791,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 791,000.00 |
| Mar 31, 2026 | 69.99 Mn |
| Dec 31, 2024 | -78,000.00 |
| Sep 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | 241.43 Mn |
| Sep 30, 2023 | -177,000.00 |
| Jun 30, 2023 | 139.00 Mn |
| Dec 31, 2022 | -63,000.00 |
| Dec 31, 2021 | 379,000.00 |
| Sep 30, 2021 | 19.10 Mn |
| Jun 30, 2021 | -23,000.00 |
| Mar 31, 2021 | 16.95 Mn |
| Dec 31, 2020 | 69.97 Mn |
| Dec 31, 2018 | 182,000.00 |
| Sep 30, 2018 | 158,000.00 |
| Jun 30, 2018 | 367,000.00 |
| Mar 31, 2018 | 25,000.00 |
| Dec 31, 2017 | 2.51 Mn |
| Sep 30, 2017 | 54,000.00 |